Principal Financial Group
GNCA

Principal Financial Group’s Genocea Biosciences, Inc. GNCA Stock Holding History

Principal Financial Group’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-27,263
Closed -$1.14M – 2263
2017
Q2 		$1.14M Hold
27,263
– – ﹤0.01% 1829
2017
Q1 		$1.33M Hold
27,263
– – ﹤0.01% 1774
2016
Q4 		$899K Buy
27,263
+1,000
+4% +$32.9K ﹤0.01% 1829
2016
Q3 		$1.08M Sell
26,263
-252
-1% -$9.89K ﹤0.01% 1760
2016
Q2 		$869K Sell
26,515
-388
-1% -$14.2K ﹤0.01% 1776
2016
Q1 		$1.67M Sell
26,903
-265
-1% -$8.42K ﹤0.01% 1662
2015
Q4 		$1.15M Buy
27,168
+38
+0.1% +$1.81K ﹤0.01% 1733
2015
Q3 		$1.49M Buy
27,130
+639
+2% +$63.4K ﹤0.01% 1709
2015
Q2 		$2.91M Buy
26,491
+2,414
+10% +$224K ﹤0.01% 1597
2015
Q1 		$2.28M Buy
24,077
+5,000
+26% +$353K ﹤0.01% 1629
2014
Q4 		$1.07M Buy
19,077
+38
+0.2% +$2.6K ﹤0.01% 1785
2014
Q3 		$1.38M Buy
19,039
+3,862
+25% +$423K ﹤0.01% 1722
2014
Q2 		$2.28M Hold
15,177
– – ﹤0.01% 1658
2014
Q1 		$2.21M Buy
+15,177
New +$1.86M ﹤0.01% 1636

Other funds holding GNCA

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

Principal Financial Group's GNCA Position: Q3 2017 in Review

Principal Financial Group sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2017, closing a stake of 27,263 shares — an estimated $1.14M sold.

Principal Financial Group first reported a position in GNCA in Q1 2014 and held it in 14 quarters. The position peaked at $2.91M in Q2 2015. 62 funds tracked by Wall St. Rank hold GNCA as of Q3 2017.

  • Principal Financial Group reported no remaining Genocea Biosciences, Inc. position as of Q3 2017 after selling out during the quarter.
  • Principal Financial Group sold 27,263 Genocea Biosciences, Inc. shares in Q3 2017, an estimated $1.14M.
  • Principal Financial Group first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 14 quarters.
  • Principal Financial Group's Genocea Biosciences, Inc. position peaked at $2.91M in Q2 2015.
  • 62 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2017.

Based on Principal Financial Group's 13F filing for Q3 2017, filed 2 Nov 2017.